Trial Profile

A one-year trial evaluating the efficacy and safety of the ALK house dust mite allergy immunotherapy tablet in adult subjects with house dust mite allergic rhinitis.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Feb 2019 According to an ALK-Abello media release, the company announced that the post-hoc analysis of this trial were were presented for the first time at this year Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI).
26 Feb 2019 Results of post-hoc analysis published in the ALK-Abello Media Release
25 Feb 2019 Results of a post-hoc analysis assessing the effect of treatment with SQ-HDM SLIT-tablet on sleep in HDM allergic rhinitis, presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com